Susquehanna Fundamental Investments LLC Has $3.19 Million Stock Position in Qiagen (NYSE:QGEN)

Susquehanna Fundamental Investments LLC lifted its stake in Qiagen (NYSE:QGEN) by 235.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 77,557 shares of the company’s stock after buying an additional 54,439 shares during the period. Susquehanna Fundamental Investments LLC’s holdings in Qiagen were worth $3,187,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Nuance Investments LLC raised its stake in shares of Qiagen by 311.0% in the first quarter. Nuance Investments LLC now owns 4,493,489 shares of the company’s stock valued at $193,175,000 after acquiring an additional 3,400,255 shares during the last quarter. Victory Capital Management Inc. raised its position in Qiagen by 104,759.6% in the 2nd quarter. Victory Capital Management Inc. now owns 1,583,380 shares of the company’s stock valued at $65,061,000 after purchasing an additional 1,581,870 shares during the last quarter. Earnest Partners LLC boosted its stake in Qiagen by 85.1% in the first quarter. Earnest Partners LLC now owns 3,427,605 shares of the company’s stock worth $147,353,000 after purchasing an additional 1,576,259 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Qiagen by 20.1% during the fourth quarter. Wellington Management Group LLP now owns 7,271,828 shares of the company’s stock worth $316,463,000 after purchasing an additional 1,217,712 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its stake in shares of Qiagen by 148.8% in the second quarter. Point72 Asset Management L.P. now owns 1,184,806 shares of the company’s stock valued at $48,684,000 after buying an additional 708,533 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Stock Up 0.5 %

Shares of QGEN stock opened at $45.24 on Monday. The firm’s fifty day moving average price is $45.20 and its two-hundred day moving average price is $43.48. The company has a current ratio of 1.77, a quick ratio of 1.46 and a debt-to-equity ratio of 0.27. Qiagen has a 1 year low of $34.74 and a 1 year high of $47.44. The firm has a market capitalization of $10.32 billion, a P/E ratio of 30.34, a PEG ratio of 3.20 and a beta of 0.39.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.03. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The business had revenue of $496.00 million during the quarter, compared to analysts’ expectations of $495.45 million. During the same period last year, the business earned $0.53 earnings per share. The firm’s revenue was down .2% on a year-over-year basis. On average, equities analysts predict that Qiagen will post 2.15 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on QGEN. Robert W. Baird raised their price objective on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Wolfe Research raised shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price target for the company in a report on Thursday, June 27th. Finally, JPMorgan Chase & Co. upped their price objective on Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, June 18th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $50.25.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.